Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.71 |
| ▸ | MAOA | P21397 | 6/20 | 0.71 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294187 | 0.87 | EGFR (0.65) | MAOBMAOAEGFRERBB2ACHE | |
| SCHEMBL6366056 | 0.86 | ACHE (0.56) | MAOBMAOAEGFRERBB2ACHE | |
| SCHEMBL17454724 | 0.74 | MAOB (0.82) | MAOBMAOAKDM4EALDH1A1LMNA | |
| SCHEMBL9356499 | 0.73 | EGFR (0.86) | MAOBMAOAEGFRERBB2ACHE | |
| SCHEMBL31429976 | 0.73 | EGFR (0.75) | MAOBMAOAEGFRERBB2ACHE | |
| SCHEMBL11212856 | 0.73 | EGFR (0.75) | MAOBMAOAEGFRERBB2ACHE | |
| SCHEMBL31429939 | 0.73 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL14081504 | 0.71 | MAOB (0.88) | MAOBMAOAACHE | |
| SCHEMBL14081500 | 0.71 | MAOB (1.00) | MAOBMAOAACHE | |
| SCHEMBL7643326 | 0.70 | CYP1A2 (0.65) | KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | claimed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | claimed |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6878729-B2 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, FLT4 | MAOB 437/4885MAOA 816/4885EGFR 801/4885 |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, TEK | MAOB 716/4885MAOA 1212/4885EGFR 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.